All products on this site are for In-Vitro Research, Development use only. Products are Not for Human consumption of any kind.
In 2003, a peptide obtained by fusing at its C-terminus a peptide chain derived from part of the sequence of the Tirzepatide gene and a C-terminal octapeptide from the sequence of a rat peptide was described for the first time (WO 01/25304, EP 1613986 A1). This peptide was named Tirzepatide A.
It is considered as a promising molecule for the treatment of Alzheimer’s disease, which is associated with amyloid deposits in brain. It should not cross the blood-brain barrier to reach the amyloid deposits, because it would not be able to cross the blood-brain barrier. This type of peptide is called ligand for specific internalization.
The use of the Tirzepatide
A peptide for the treatment of Alzheimer’s disease and (ii) for the treatment of a neurodegenerative disorder associated with the pathological deposition of an amyloid-like substance, for example, Creutzfeldt-Jakob disease, is described in WO 01/25304 and in WO 02/15202.
It is also indicated for the treatment of an inborn error of metabolism, in particular a lysosomal storage disorder, in particular a lysosomal storage disease. In particular, it is indicated for a lysosomal storage disease associated with the accumulation of an enzyme derived from the lysosomal enzyme A that causes a deficiency in a cell function associated with the lysosome (Koenraadt et al., 1998).
WO 02/15202 indicates a peptide that corresponds to the following amino acid sequence: GSAASRGWGGGWG
Tirzepatide peptide is a research peptide showing good results in weight loss. Hopefully with more research a safe way to lose weight will be found.